Table 32.

Antimicrobial resistance in Campylobacter jejuni from humans per country in 2016

Country	Gentamicin		Co‐amoxiclav		Ciprofloxacin		Erythromycin		Tetracyclines
	N	% Res	N	% Res	N	% Res	N	% Res	N	% Res
Austria	376	0.3	–	–	376	71.5	376	0	376	41.5
Cyprus	–	–	–	–	38	86.8	38	0	38	86.8
Denmark	294	0.7	–	–	294	33.3	294	1.0	294	16.0
Estonia	–	–	–	–	194	91.2	196	0	196	63.8
Finlanda	–	–	–	–	2,923	61.0	2,776	2.8	1,097	44.2
Franceb	5,108	0.3	5,614	0.2	5,616	55.3	5,615	0.6	5,390	46.8
Italy	74	4.1	–	–	80	85.0	80	3.8	80	67.5
Lithuaniab	–	–	–	–	289	86.9	329	6.1	275	63.6
Luxembourg	–	–	457	4.8	457	63.2	457	0.2	457	46.2
Malta	7	NA	8	NA	134	55.2	133	5.3	8	NA
Netherlandsb	–	–	–	–	2,401	56.1	2,102	1.9	1,715	39.0
Portugal	167	0.6	–	–	167	94.0	167	6.6	167	82.0
Romania	18	0	18	0	18	77.8	18	0	18	44.4
Slovakiab	34	2.9	109	2.8	639	51.8	862	1.0	665	27.2
Slovenia	–	–	–	–	1,192	66.4	1,193	0.4	1,192	37.2
Spain	265	1.1	–	–	265	84.5	265	2.6	265	78.5
United Kingdomb	32	0	–	–	7,593	44.4	7,092	3.3	3,381	36.3
Total (17 MSs)	6,375	0.4	6,206	0.6	22,676	54.6	21,993	2.1	15,614	42.8
Icelandb	–	–	–	–	60	13.3	60	0.0	–	–
Norway	173	0.6	–	–	171	41.5	173	11.6	173	19.7

N: number of isolates tested; % Res: percentage of resistant isolates (either non‐wild type by ECOFFs or clinically non‐susceptible by combining resistant and intermediate categories); –: no data reported; NA: not applicable – if fewer than 10 isolates were tested, resistance was not calculated.

^aTravel‐associated cases, accounting for 75% of Campylobacter infections in Finland in 2015, could not be excluded from the Finnish AST data.

^bData interpreted with clinical breakpoints.